March 2013

 

Issue

Supplement

Editor’s Page

By Robert L. Avery, MD; and Allen C. Ho, MD;

Medical Volunteerism Abroad

Volunteer-based missions bring ophthalmologists the chance to offer their skills to those in need.

By Rachel M. Renshaw, Editor-in-Chief

Business of Retina

The Office of the Inspector General and You

By George A. Williams, MD

Medical Device Regulation: A Review

By Aron Shapiro; Maureen O’Connell; and Ryan Bouchard

Retina Surgery

Giant Retinal Tears: Size Does Matter

Pearls for managing a variety of surgical scenarios.

By Manish Nagpal, MS, DO, FRCS(UK)

Natural Dyes for Chromovitrectomy

The efficacy of natural dyes in ocular surgery is under investigation.

By Eduardo A. Novais, MD; Eduardo B. Rodrigues, MD; Magno Antonio Ferreira, MD; ane Chen, MD; André Maia, MD; Maurício Maia, MD; Emmerson Badaró, MD; Fernando M. Penha, MD; and Michel Eid Farah, MD

Oncology

Strategies for Minimizing Radiation Maculopathy

By Spenser J. Morton, BS; Priya Sharma, BS; and Carol L. Shields, MD

Cover Stories

The Microplasmin for Pediatric Vitrectomy Study

Ocriplasmin has been evaluated in children in a phase 2 trial; results have not been announced.

By Kimberly Drenser, MD, PhD

Update on FEVR: Diagnosis, Management, and Treatment

This lifelong disease requires prompt treatment and vigilant follow-up.

By Franco M. Recchia, MD

Telemedicine for ROP: An Update

A remote screening program can leverage the efforts of a single skilled screener.

By Darius M. Moshfeghi, MD

Papillophlebitis in a Young Girl Secondary to Homozygous Mutation of MTHFR C677T and A1298C Genotypes

By Kiran Turaka, MD; Matthew C. Ziemianski, MD; and J. Shepard Bryan, MD

Update on Anti-VEGF Treatment for ROP

Some promising results with VEGF inhibition, but laser remains the standard of care.

By Michael T. Trese, MD

Special Cover Features: Medical Innovation in Retina

Integrin Peptide Therapy for the Treatment of Vascular Eye Diseases

In addition to its effects in DME, this molecule can induce posterior vitreous detachment.

By Baruch D. Kuppermann, MD, PhD

Vitreomacular Adhesion: Pathology and Treatment

New pharmacologic treatment option is an alternative to surgery or watchful waiting.

By David S. Boyer, MD

Departments

Innovations

5Q With Michael T. Trese, MD

Dr. Trese is a Clinical Professor of Ophthalmology at The Eye Research Institute of Oakland University, a Clinical Associate Professor at Wayne State University School of Medicine, and the Chief of Pediatric and Adult Vitreoretinal Surgery at William Beaumont Hospital in Michigan.

Insurer Perspective on Bevacizumab for ROP

By Arthur W. Allen Jr, MD
 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Bryan Bechtel
Editor-in-Chief
484-581-1827
bbechtel@bmctoday.com

Alan B. Guralnick
Publisher
484-581-1832
aguralnick@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.

Website Design by Sides Media